What are the clinical benefits of recombinant gonadotrophins? Is Puregon a 'good' or 'super' drug?

Human Reproduction

Volumn 14, Issue 6, 1999, Pages 1409-1411

  Godwin, I Meniru ^a,b  

^a Jerudong Park Medical Centre   (Brunei Darussalam)

^b AULTMAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOLLITROPIN; RECOMBINANT PROTEIN;

FEMALE; FERTILIZATION IN VITRO; HUMAN; OVARY HYPERSTIMULATION; PREGNANCY; REVIEW; RISK FACTOR;

FEMALE; FERTILIZATION IN VITRO; FOLLICLE STIMULATING HORMONE; FOLLICLE STIMULATING HORMONE, HUMAN; HUMANS; OVARIAN HYPERSTIMULATION SYNDROME; PREGNANCY; RECOMBINANT PROTEINS; RISK FACTORS;

EID: 0033142551     PISSN: 02681161     EISSN: None     Source Type: Journal    
DOI: 10.1093/humrep/14.6.1409     Document Type: Article

References (12)

1. Aboulghar, M.A., Mansour, R.T., Serour, G.I. et al. (1996) Recombinant follicle stimulating-hormone in the treatment of patients with history of severe ovarian hyperstimulation syndrome. Fertil. Steril., 66, 757-760.
2. . Devroey, P., Mannaerts, B.M.J.L., Smitz, J. et al. (1994) Clinical outcome of a pilot efficacy study on recombinant human follicle-stimulating hormone (Org 32489) combined with various gonadotrophin-releasing hormone agonist regimens. Hum. Reprod., 9, 1064-1069.
3. Devroey, P., Tournaye, H., Van Steirteghem, A. et al. (1998) The use of a 100 IU starting dose of recombinant follicle stimulating hormone (Puregon) in in-vitro fertilization. Hum. Reprod., 13, 565-566.
4. Edwards, R.G., Lobo, R. and Bouchard, P. (1996) Time to revolutionize ovarian stimulation. [Editorial.] Hum. Reprod., 11, 917-919.
5. Hedon, B., Out, H.J., Hugues, J.N. et al. (1995) Efficacy and safety of recombinant follicle stimulating hormone (Puregon) in infertile women pituitary-suppressed with triptorelin undergoing in-vitro fertilization: a prospective, randomized, assessor-blind, multicentre trial. Hum. Reprod., 10, 3102-3106.
6. Jacob, S., Drudy, L., Conroy, R. and Harrison, R.F. (1998) Outcome from consecutive in-vitro fertilization/intracytoplasmic sperm injection attempts in the final group treated with recombinant follicle stimulating hormone. Hum. Reprod., 13, 1783-1787.
7. Lesny, P., Killick, S.R., Tetlow, R.L. et al. (1998) Embryo transfer-can we learn anything new from the observation of junctional zone contractions? Hum. Reprod., 13, 1540-1546.
8. Out, HJ., Mannaerts, B.M.J.L., Driessen, S.G.A.L. état. (1995) A prospective, randomized, assessor-blind, multicentre study comparing recombinant and urinary follicle stimulating hormone (Puregon versus Metrodin) in in-vitro fertilization. Hum. Reprod., 10, 2534-2540.
9. Out, HJ., Bernadelte, M.J.L., Mannaerts, B.M.J.L. étal. (1996a) Recombinant follicle stimulating hormone (rFSH; Puregon) in assisted reproduction: More oocytes, more pregnancies. Results from five comparative studies. Hum. Reprod. Update, 2, 162-171.
10. Out, H.J., Reimitz, P.E. and Coelingh Bennink, J.T. (1996b) A prospective, randomized study to assess the tolerance and efficacy of-intramuscular and subcutaneous administration of recombinant follicle-stimulating hormone (Puregon). Fertil. Steril., 67, 278-283.
11. Out, HJ., Driessen, S.G.A. Bernadette, M.J.L. et al. (1997) Recombinant follicle-stimulating hormone (follitropin beta, Puregon) yields higher pregnancy rates in in vitro fertilization than urinary gonadotropins. Fertil. Steril., 68, 138-142.
12. Recombinant Human FS H Study Group (1995) Clinical assessment of recombinant human follicle-stimulating hormone in stimulating ovarian follicular development before in vitro fertilization. Fertil. Steril., 63, 77-86.